Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of EDG-7500 in Participants With Impaired and Normal Hepatic Function

The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of…

Hepatic Impairment (HI)

Estimated

~$10 – $8,750

Edgewise Therapeutics, Inc.NCT07324616